Jahanara Rajwani

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Correction: The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

Correction: The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

Journal: PloS one
Published: June 22, 2026

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Journal: Nature cancer
Published: April 29, 2026

The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53-/- murine model of sarcoma.

The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53-/- murine model of sarcoma.

Journal: Oncoimmunology
Published: July 22, 2025

The role of non-cancer cell infections in oncolytic virus therapy.

The role of non-cancer cell infections in oncolytic virus therapy.

Journal: Seminars in immunology
Published: May 07, 2025

The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells.

The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells.

Journal: Science immunology
Published: November 01, 2024

VSV∆M51 drives CD8+ T cell-mediated tumour regression through infection of both cancer and non-cancer cells.

VSV∆M51 drives CD8+ T cell-mediated tumour regression through infection of both cancer and non-cancer cells.

Journal: Nature communications
Published: October 11, 2023

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.

Journal: Communications biology
Published: August 12, 2021

The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

Journal: PloS one
Published: February 16, 2021

Author Correction: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.

Author Correction: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.

Journal: Nature communications
Published: May 26, 2018

Rhabdoviruses as vaccine platforms for infectious disease and cancer.

Rhabdoviruses as vaccine platforms for infectious disease and cancer.

Journal: Biotechnology & genetic engineering reviews
Published: May 22, 2018

Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA.

Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA.

Journal: The Journal of infectious diseases
Published: April 27, 2018

Genetic analysis of ID1-DBL2X predicts its validity as a vaccine candidate in Colombia and supports at least two independently introduced Plasmodium falciparum populations in the region.

Genetic analysis of ID1-DBL2X predicts its validity as a vaccine candidate in Colombia and supports at least two independently introduced Plasmodium falciparum populations in the region.

Journal: Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
Published: May 13, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026